Intersect ENT, Inc. (NASDAQ:XENT) COO Richard E. Kaufman sold 13,639 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $28.97, for a total value of $395,121.83. Following the completion of the sale, the chief operating officer now owns 133,757 shares of the company’s stock, valued at approximately $3,874,940.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Intersect ENT, Inc. (NASDAQ:XENT) traded up 0.52% during trading on Thursday, reaching $28.80. The company had a trading volume of 93,510 shares. The stock’s 50-day moving average price is $30.56 and its 200-day moving average price is $24.46. The company’s market capitalization is $840.64 million. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $33.25.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company had revenue of $24.00 million during the quarter, compared to analyst estimates of $22.62 million. During the same period in the previous year, the business earned ($0.21) EPS. Intersect ENT’s quarterly revenue was up 24.4% on a year-over-year basis. On average, equities analysts expect that Intersect ENT, Inc. will post ($0.61) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Intersect ENT, Inc. (XENT) COO Richard E. Kaufman Sells 13,639 Shares of Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/28/intersect-ent-inc-xent-coo-richard-e-kaufman-sells-13639-shares-of-stock.html.

Several institutional investors have recently modified their holdings of XENT. Wellington Management Group LLP lifted its holdings in Intersect ENT by 0.4% in the first quarter. Wellington Management Group LLP now owns 2,921,012 shares of the medical equipment provider’s stock valued at $50,095,000 after acquiring an additional 10,683 shares during the last quarter. FMR LLC lifted its holdings in Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after acquiring an additional 1,056,389 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Intersect ENT by 6.7% in the second quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock valued at $31,853,000 after acquiring an additional 71,750 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after acquiring an additional 898,785 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in Intersect ENT by 49.8% in the first quarter. Neuberger Berman Group LLC now owns 884,627 shares of the medical equipment provider’s stock valued at $15,171,000 after acquiring an additional 293,949 shares during the last quarter. Institutional investors and hedge funds own 83.12% of the company’s stock.

A number of analysts have commented on the company. Bank of America Corporation upped their price target on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Canaccord Genuity upped their price target on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. TheStreet upgraded Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Finally, BidaskClub cut Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Intersect ENT has an average rating of “Buy” and an average price target of $27.11.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.